Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer, as well as ASC08/Danoprevir, a protease inhibitor for hepatitis C virus. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASLAN001/Varlitinib, a pan-HER2 inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; Prexasertib/LY2606368, a chk-1 inhibitor for cancer; LOXO-101, a PanTrk inhibitor for cancer; and ONT-380/ARRY-380, an HER2 inhibitor for breast cancer. The company's Phase I drugs include GDC-0994, an ERK inhibitor for cancer; and ARRY-382, a CSF1R inhibitor for cancer, as well as Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Array BioPharma (ARRY) announced on Monday that the company's treatment for metastatic melanoma met its primary endpoint in a late-stage clinical trial.
Posted this in daily thread this morning and came close to selling @ 6.40 but decided to hold off on that for now Array BioPharma (ARRY) Stock Soars on Drug Success, Piper Jaffray Ups Price Target
ok, could not pass up $7.05 exit so out for now and may be kicking myself in the morning but i am an impatient and scared trader, especially with clinton up tonight
38% is nothing to be sad about AND i'm an impatient and scared trader even without upcoming elections Plus won't be around in the morning (editing to include @ open) to watch and this thing is in overbought territory so being safe, especially with the impact clinton might have had but not much in the way of health came up in the mud slinging show tonight
Weekly Chart - nice breakout above the 100, 200 & 300 DMA's - 8 is going to be the next big level to break
Shares of Array BioPharma ($ARRY) are under pressure in pre-market trading after the biopharmaceutical company said it has withdrawn its new drug application for binimetinib monotherapy for the treatment of NRAS-mutant melanoma.
